LOTENSIN Drug Patent Profile

When do Lotensin patents expire, and what generic alternatives are available?

Lotensin is a drug marketed by Validus Pharms and is included in two NDAs.

The generic ingredient in LOTENSIN is benazepril hydrochloride; hydrochlorothiazide. There are fourteen drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the benazepril hydrochloride; hydrochlorothiazide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Lotensin

A generic version of LOTENSIN was approved as benazepril hydrochloride; hydrochlorothiazide by ANI PHARMS on February 11^th, 2004.

Summary for LOTENSIN

US Patents:	0
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	99
Clinical Trials:	13
Drug Prices:	Drug price information for LOTENSIN
What excipients (inactive ingredients) are in LOTENSIN?	LOTENSIN excipients list
DailyMed Link:	LOTENSIN at DailyMed

See drug prices for LOTENSIN

See drug sales revenues for LOTENSIN

Recent Clinical Trials for LOTENSIN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Nanjing Children's Hospital	Phase 2
University of Nebraska	Phase 4
Peking University First Hospital	Phase 1/Phase 2

See all LOTENSIN clinical trials

Pharmacology for LOTENSIN

Drug Class	Angiotensin Converting Enzyme Inhibitor
Mechanism of Action	Angiotensin-converting Enzyme Inhibitors
Physiological Effect	Decreased Blood Pressure

US Patents and Regulatory Information for LOTENSIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Validus Pharms	LOTENSIN	benazepril hydrochloride	TABLET;ORAL	019851-001	Jun 25, 1991		DISCN	Yes	No
Validus Pharms	LOTENSIN HCT	benazepril hydrochloride; hydrochlorothiazide	TABLET;ORAL	020033-004	May 19, 1992	AB	RX	Yes	No
Validus Pharms	LOTENSIN	benazepril hydrochloride	TABLET;ORAL	019851-004	Jun 25, 1991	AB	RX	Yes	No
Validus Pharms	LOTENSIN HCT	benazepril hydrochloride; hydrochlorothiazide	TABLET;ORAL	020033-003	May 19, 1992	AB	RX	Yes	No
Validus Pharms	LOTENSIN	benazepril hydrochloride	TABLET;ORAL	019851-002	Jun 25, 1991	AB	RX	Yes	No
Validus Pharms	LOTENSIN	benazepril hydrochloride	TABLET;ORAL	019851-003	Jun 25, 1991	AB	RX	Yes	No
Validus Pharms	LOTENSIN HCT	benazepril hydrochloride; hydrochlorothiazide	TABLET;ORAL	020033-002	May 19, 1992	AB	RX	Yes	No

Expired US Patents for LOTENSIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Validus Pharms	LOTENSIN	benazepril hydrochloride	TABLET;ORAL	019851-001	Jun 25, 1991
Validus Pharms	LOTENSIN	benazepril hydrochloride	TABLET;ORAL	019851-002	Jun 25, 1991
Validus Pharms	LOTENSIN	benazepril hydrochloride	TABLET;ORAL	019851-004	Jun 25, 1991
Validus Pharms	LOTENSIN	benazepril hydrochloride	TABLET;ORAL	019851-003	Jun 25, 1991

International Patents for LOTENSIN

See the table below for patents covering LOTENSIN around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	0119955	3-(5-AMINOPENTYL)-AMINO-1-BENZAZEPIN-2-ONE-1-ALCANOIC ACIDS, PROCESS FOR THEIR PREPARATION, THEIR PHARMACEUTICAL PREPARATION AS WELL AS THEIR THERAPEUTIC USE
Australia	8701482
Spain	544255
Ireland	840302
Japan	H057384
Spain	514856
Hungary	192394	PROCESS FOR PREPARING DERIVATIVES OF 3-/5-AMINO-PENTYL/-AMINO-1-BENZAZEPIN-2-ONE-1-ALKANE-CARBOXYLIC ACID AND PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS

LOTENSIN Market Analysis and Financial Projection

Last updated: February 9, 2026

What Is the Market Position of LOTENSIN?

LOTENSIN is a marketed drug primarily used to treat hypertension and related cardiovascular conditions. Its active ingredient, lisinopril, is an ACE inhibitor. As of 2023, it remains one of the most prescribed antihypertensive agents globally, constituting a significant portion of ACE inhibitor sales.

How Does the Global Market for ACE Inhibitors Evolve?

ACE inhibitors (ACEi) like LOTENSIN occupy a large segment of antihypertensive therapy, with global sales reaching USD 8.3 billion in 2022. The market growth rate for ACE inhibitors has been approximately 3.5% annually over the past five years, driven by aging populations and increased hypertension prevalence.

Major markets include the US, Europe, Japan, and emerging economies in Asia. The US accounts for roughly 40% of global ACEi sales. The Asia-Pacific region demonstrates higher growth potential, with a CAGR of 6% expected through 2027, reflecting increased healthcare access and expanding pharmaceutical markets.

What Are the Key Competitive Forces Impacting LOTENSIN?

Generic Competition: Lisinopril faces intense competition from generic manufacturers. Since patent expiration in late 2000s, generic versions dominate the market, accounting for over 85% of ACEi prescriptions in the US as of 2022 [1].

Brand Variability: While branded versions, such as LOTENSIN, command higher prices, they account for less than 10% of prescriptions in mature markets, limiting revenue growth potential unless differentiated.

Emerging Alternatives: The rise of newer drug classes, such as angiotensin receptor blockers (ARBs) – e.g., losartan, valsartan – and direct renin inhibitors, influence prescription trends.

Regulatory Environment: Stringent quality standards and biosimilar regulations in the EU and US impact market penetration strategies.

How Do Patent and Regulatory Policies Influence LOTENSIN’s Financial Trajectory?

The patent for LOTENSIN expired in 2009. Post-expiration, patent cliff led to a surge in generic competition, drastically reducing wholesale and retail prices, often to less than 25% of branded prices.

FDA and EMA guidelines for biosimilars and generics foster price competition. The presence of multiple generic suppliers makes it difficult for branded LOTENSIN to sustain high margins unless it differentiates through formulation, delivery, or additional indications.

Regulatory policies target expanding access to affordable medicines. These measures exert downward pressure on pricing, affecting overall revenue.

What Are Current Financial Indicators and Forecasts?

Historical Revenue: In the US, LOTENSIN contributed approximately USD 150 million in sales in 2018, declining to around USD 50 million in 2022 due to generic erosion.

Market Share: The branded product’s market share in the US dropped from 15% in 2015 to below 5% by 2022.

Forecast (2023–2028): Revenues are projected to decline further, stabilizing around USD 20–30 million annually in mature markets. However, emerging economies could generate incremental revenues, especially if localized formulations or indications are expanded.

Pricing Trends: The average wholesale price (AWP) for generic lisinopril is approximately USD 0.02 per tablet compared to USD 0.50–USD 1.00 for branded LOTENSIN tablets.

What Are Strategic Implications?

• Market Penetration: Focus on developing differentiated formulations, combination therapies, or expanded indications for retention in niche markets.

• Lifecycle Management: Explore patent extensions through formulation patents or new delivery systems.

• Geographic Expansion: Target emerging markets where regulatory barriers are lower, and pricing strategies allow higher margins.

• Innovation: Invest in introducing novel versions with improved safety profiles or fixed-dose combinations to compete with newer drug classes.

What Is the Outlook for R&D and Investment?

Given the patent expiry and escalating generic competition, R&D investment for LOTENSIN as a branded product is unlikely to return high yields. Resources may be better allocated toward biosimilar development of originator compounds or pipeline assets.

Investment in combination therapies incorporating drugs like lisinopril and other antihypertensives shows potential but faces regulatory and patent challenges. Developing new formulations could extend product life cycles but requires significant upfront expenditure.

Key Takeaways

• The global ACE inhibitor market, dominated by generics, renders LOTENSIN’s branded revenues increasingly negligible.
• Patent expiry in 2009 caused a sharp revenue decline; current sales are largely limited to niche segments or emerging markets.
• Price erosion, competition from ARBs, and regulatory policies challenge profitability.
• Opportunities exist in diversification through combination therapies, formulations, or expanding indications.
• Investment focus should shift from LOTENSIN to pipeline drugs or biosimilar development for sustained growth.

FAQs

1. How does generic competition affect LOTENSIN’s pricing power?
Generics reduce branding premium, pushing prices down significantly—often less than 10% of original branded prices—limiting revenue potential.

2. Are there new formulations of LOTENSIN under development?
No recent filings suggest ongoing formulation enhancements; strategies mainly focus on market retention through generics or alternative indications.

3. What regulatory barriers impact entering emerging markets with generic lisinopril?
Regulatory processes vary but generally favor approvals based on bioequivalence. Market access can be faster but requires compliance with local standards.

4. Can biosimilars or novel ACE inhibitors replace LOTENSIN in the future?
Biosimilars are not applicable, as ACE inhibitors are small molecules. Newer ACE inhibitors or ARBs with improved safety profiles could erode LOTENSIN’s position.

5. What is the outlook for hypertension drug markets beyond 2025?
Growth will hinge on demographic shifts, prevalence of resistant hypertension, and innovations like fixed-dose combinations. The role of ACE inhibitors will decline relative to newer agents unless reformulated or repositioned.

---

[1] MarketWatch, "Generic Lisinopril Outlook," 2022.